
Pioneering AI Drug Discovery | Recursion
All of our results feed back into our drug discovery and drug development platform – the Recursion Operating System – in a continuously improving feedback loop.
Recursion's Drug Discovery Pipeline | Recursion
Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high …
Our Unique Approach to AI Drug Discovery | Recursion
Delve into Recursion's unique TechBio approach. Discover how we're revolutionizing AI drug discovery and the biotech industry. Read more about our approach today!
Recursion OS:
By leveraging Recursion’s vast data universe and machine learning models at every stage of the discovery, design and delivery process, we are able to rapidly validate and accelerate high …
Recursion Pharmaceuticals, Inc. - MIT and Recursion Release Boltz …
Jun 6, 2025 · Powered by Recursion's NVIDIA supercomputer for its training and validation, this next-generation AI model achieves best-in-class accuracy in jointly modeling complex …
LOWE - Recursion
Within Recursion, this process typically requires biologists to delineate biological pathways and establish novel map relationships, followed by chemists optimizing chemical series for the …
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. - Recursion and Exscientia, two …
Nov 20, 2024 · “I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” …
Accelerating AI Drug Discovery with Open Source Datasets
May 28, 2025 · That’s why we’ve not only been building massive fit-for-purpose datasets at Recursion, but releasing smaller open source versions of these datasets to accelerate the …
Recursion Reports Third Quarter 2025 Financial Results and …
Oct 9, 2025 · Sanofi continues to leverage combined Recursion OS 2.0, including phenomics, to identify new program opportunities. Recursion and Sanofi are further advancing and …